Pacira BioSciences, Inc. (PCRX): Price and Financial Metrics

PCRX POWR Grades

• Growth is the dimension where PCRX ranks best; there it ranks ahead of 95.94% of US stocks.
• The strongest trend for PCRX is in Quality, which has been heading up over the past 179 days.
• PCRX's current lowest rank is in the Momentum metric (where it is better than 9.4% of US stocks).

PCRX Stock Summary

• With a one year PEG ratio of 518, PACIRA BIOSCIENCES INC is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than 94.11% of US stocks.
• With a year-over-year growth in debt of -25.34%, PACIRA BIOSCIENCES INC's debt growth rate surpasses merely 12.62% of about US stocks.
• Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for PCRX comes in at 14.36% -- higher than that of 87.69% of stocks in our set.
• Stocks with similar financial metrics, market capitalization, and price volatility to PACIRA BIOSCIENCES INC are STER, CPRX, CVLT, ZIP, and QTRX.
• Visit PCRX's SEC page to see the company's official filings. To visit the company's web site, go to www.pacira.com.

PCRX Valuation Summary

• In comparison to the median Healthcare stock, PCRX's price/sales ratio is 21.05% higher, now standing at 2.3.
• Over the past 154 months, PCRX's EV/EBIT ratio has gone up 74.7.

Below are key valuation metrics over time for PCRX.

PCRX Growth Metrics

Its 5 year net income to common stockholders growth rate is now at 99.84%.
• The 2 year net income to common stockholders growth rate now stands at 44796.51%.
• Its 5 year net cashflow from operations growth rate is now at 100.19%.

Over the past 33 months, PCRX's revenue has gone up $233,036,000.

The table below shows PCRX's growth in key financial areas (numbers in millions of US dollars).

Date	Revenue	Operating Cash Flow	Net Income to Common Stock
2022-09-30	654.062	126.452	20.881
2022-06-30	614.318	144.085	39.234
2022-03-31	580.497	144.413	38.439
2021-12-31	541.533	125.717	41.98
2021-09-30	513.313	149.169	61.625
2021-06-30	503.075	128.663	174.084

PCRX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.

• PCRX has a Quality Grade of C, ranking ahead of 72.8% of graded US stocks.
• PCRX's asset turnover comes in at 0.394 -- ranking 116th of 681 Pharmaceutical Products stocks.
• BCDA, NVAX, and RDHL are the stocks whose asset turnover ratios are most correlated with PCRX.

The table below shows PCRX's key quality metrics over time.